MS Views and News Be empowered with MS views and news. To receive The MS BEACON e-Newsletter, CLICK HERE - -

Visit our MS learning channel on YouTube, which provides hundreds of MS educational videos presented by MS Experts from across the USA. Archived here: -- Also please visit our Social media platforms: Facebook, Twitter, and Instagram . Each providing important information for the MS community. Furthermore, scroll down the left side of this blog to learn from the resources and links.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, for your personal knowledge and to keep you informed of current health-related issues. It is not a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.


Saturday, April 18, 2009

Biogen Idec wins approval for high titer production of multiple sclerosis drug


Apr 17, 2009 (Datamonitor via COMTEX) -- -- Biogen Idec, a manufacturer of biologics, has reported that the FDA has approved the company's high titer process for the production of its multiple sclerosis drug Tysabri.

Biogen Idec has received similar approval from the European Medicines Agency for the high titer process in December 2008. The new, higher-yield process will be used to manufacture Tysabri at the company's plant in Research Triangle Park.

Tysabri, which is co-marketed with Elan, is approved in more than 40 countries. Tysabri is approved in the US for relapsing forms of multiple sclerosis and moderately-to-severely active Crohn's disease. It is approved in the EU for relapsing-remitting multiple sclerosis.

Bob Hamm, COO of Biogen Idec, said: "Developing this high titer process is another example of our world-class expertise and leadership in biologics manufacturing. We expect this new process to result in about a four-fold increase in yield."
Republication or redistribution, including by framing or similar means,
is expressly prohibited without prior written consent. Datamonitor shall
not be liable for errors or delays in the content, or for any actions
taken in reliance thereon
For full details on Biogen Idec Inc (BIIB) click here. Biogen Idec Inc (BIIB) has Short Term PowerRatings of 7.
Details on Biogen Idec Inc (BIIB) Short Term PowerRatings is available at This Link.


1 comment:

Anonymous said...

But will this reduce the cost of my treatment? Almost 10k a month is insane!